PZ0389
PF-06869206
≥98% (HPLC)
别名:
(S)-3-Chloro-7-(2-(hydroxymethyl)morpholino)-2-methyl-5-(trifluoromethyl)-1H-pyrrolo[3,2-b]pyridine-6-carbonitrile, PF 06869206, PF06869206
InChI
1S/C15H14ClF3N4O2/c1-7-10(16)11-12(21-7)13(23-2-3-25-8(5-23)6-24)9(4-20)14(22-11)15(17,18)19/h8,21,24H,2-3,5-6H2,1H3/t8-/m0/s1
InChI key
ATFQBBCQZKVZJN-QMMMGPOBSA-N
SMILES string
ClC1=C(C)NC2=C1N=C(C(F)(F)F)C(C#N)=C2N3C[C@@H](CO)OCC3
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
room temp
Application
PF-06869206 has been used to selectively inhibit the activity of sodium-phosphate cotransporter 2a (NaPi2a).
Biochem/physiol Actions
PF-06869206 is a selective inhibitor against sodium-phosphate cotransporter 2A (NaPi-2a, NaPi-Iia, Na+/Pi cotransporter 2A, Na+-dependent phosphate cotransporter 2A).
PF-06869206 may be used to treat patients with mineral and hormonal derangements linked with increased cardiovascular risk in chronic kidney disease. This drug might also improve urinary phosphate excretion. PF-06869206 has an ability to decrease phosphate uptake in human embryonic kidney (HEK) cells transfected with mouse or rat renal sodium-dependent phosphate transporter genes (Npt2a).
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Synthesis of PF-06869206
Kocienski P
Synfacts, 14(07), 0675-0675 (2018)
Discovery of Orally Bioavailable Selective Inhibitors of the Sodium-Phosphate Cotransporter NaPi2a (SLC34A1)
Filipski KJ, et al.
ACS Medicinal Chemistry Letters, 9(5), 440-445 (2018)
In vivo effects of renal Npt2a inhibition
Thomas L, et al.
Faseb Journal, 33(1-supplement), 751-752 (2019)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持